Volume | 643,302 |
|
|||||
News | - | ||||||
Day High | 32.26 | Low High |
|||||
Day Low | 31.32 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Agios Pharmaceuticals Inc | AGIO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
32.08 | 31.32 | 32.26 | 31.67 | 31.81 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
8,761 | 643,302 | $ 31.70 | $ 20,391,245 | - | 19.795 - 35.48 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:09:56 | average | 98,811 | $ 31.67 | USD |
Agios Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.78B | 56.19M | - | 26.82M | -352.09M | -6.27 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Agios Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AGIO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 28.93 | 33.02 | 28.71 | 30.32 | 777,419 | 2.74 | 9.47% |
1 Month | 29.24 | 33.02 | 27.14 | 29.45 | 661,681 | 2.43 | 8.31% |
3 Months | 22.79 | 35.48 | 22.23 | 29.38 | 763,593 | 8.88 | 38.96% |
6 Months | 20.97 | 35.48 | 19.795 | 25.77 | 729,295 | 10.70 | 51.03% |
1 Year | 22.64 | 35.48 | 19.795 | 25.69 | 581,134 | 9.03 | 39.89% |
3 Years | 55.14 | 62.155 | 16.75 | 31.32 | 597,762 | -23.47 | -42.56% |
5 Years | 58.39 | 62.155 | 16.75 | 36.91 | 641,619 | -26.72 | -45.76% |
Agios Pharmaceuticals Description
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval. |